0001415889-24-008561.txt : 20240319 0001415889-24-008561.hdr.sgml : 20240319 20240319163653 ACCESSION NUMBER: 0001415889-24-008561 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240315 FILED AS OF DATE: 20240319 DATE AS OF CHANGE: 20240319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stevens Raymond C CENTRAL INDEX KEY: 0001698149 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41608 FILM NUMBER: 24764006 MAIL ADDRESS: STREET 1: 2200 PENNSYLVANIA AVENUE STREET 2: SUITE 800W CITY: WASHINGTON STATE: DC ZIP: 20037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Structure Therapeutics Inc. CENTRAL INDEX KEY: 0001888886 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981480821 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD SUITE 223 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (628) 229-9277 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD SUITE 223 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: ShouTi Inc. DATE OF NAME CHANGE: 20211019 4 1 form4-03192024_080344.xml X0508 4 2024-03-15 0001888886 Structure Therapeutics Inc. GPCR 0001698149 Stevens Raymond C C/O STRUCTURE THERAPEUTICS INC. 601 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080 true true false false CHIEF EXECUTIVE OFFICER 0 Ordinary Shares 2024-03-15 4 A 0 134682 0 A 1198346 D Ordinary Shares 1554586 I See footnote Stock Option (right to buy) 35.25 2024-03-15 4 A 0 335481 0 A 2034-03-14 Ordinary Shares 335481 335481 D Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2024, subject to Reporting Person's continued service on such dates. By Raymond Stevens and Vivian Urena-Stevens, as Co-Trustees of the Stevens 2001 Revocable Trust, dated March 28, 2001. 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. /s/ Jun Yoon, Attorney-in-Fact 2024-03-19